Genotyping assay to predict cytochrome P4503A5 (SJ-01-0005)
- *Abstract
-
CYP3A5 is an important contributor in drug clearance and involved in regulating the levels of endogenous paracrine or endocrine factors in certain organs such as the kidneys. Two single nucleotide polymorphisms found in CYP3A5 have been identified that result in splice variants, which contribute to decreased levels of CYP3A5 protein. A diagnostic assay detecting these mutations would be an important tool in identifying appropriate therapeutic treatments for individual patients.
Key words: Drug metabolism
Granted patents and published applications: US Patent No. 7,022,475
Related scientific references: Givens et al., "CYP3A5 genotype predicts renal CYP3A activity and blood pressure in healthy adults", J Appl Physiol 95:1297-1300, 2003;
Lin et al., "Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism", Mol Pharmacol 62(1):162-172, 2002;
Lambda et al., "Common allelic variants of cytochrome P4503A4 and their prevalence in different populations", Pharmacogenetics 12(2):121-132, 2002.
- 國家/地區
- 美國
